These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21057464)

  • 1. Novartis eyes oral MS drug as potential blockbuster.
    Ratner M
    Nat Biotechnol; 2010 Nov; 28(11):1135-6. PubMed ID: 21057464
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple sclerosis: closing in on an oral treatment.
    Martin R
    Nature; 2010 Mar; 464(7287):360-2. PubMed ID: 20237554
    [No Abstract]   [Full Text] [Related]  

  • 3. Trial watch: Phase III promise for oral multiple sclerosis therapy.
    Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180099
    [No Abstract]   [Full Text] [Related]  

  • 4. Fingolimod for multiple sclerosis.
    Drug Ther Bull; 2012 Feb; 50(2):18-20. PubMed ID: 22329953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fingolimod therapy for multiple sclerosis.
    Willis MA; Cohen JA
    Semin Neurol; 2013 Feb; 33(1):37-44. PubMed ID: 23709211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fingolimod for the treatment of relapsing multiple sclerosis.
    Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K
    Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infections cast cloud over Novartis' MS therapy.
    Garber K
    Nat Biotechnol; 2008 Aug; 26(8):844-5. PubMed ID: 18688218
    [No Abstract]   [Full Text] [Related]  

  • 8. Drugs: An injection of hope.
    Graham-Rowe D
    Nature; 2012 Apr; 484(7393):S4. PubMed ID: 22509505
    [No Abstract]   [Full Text] [Related]  

  • 9. Oral fingolimod (gilenya) for multiple sclerosis.
    Med Lett Drugs Ther; 2010 Dec; 52(1353-1354):98-9. PubMed ID: 21344782
    [No Abstract]   [Full Text] [Related]  

  • 10. A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).
    Chun J; Brinkmann V
    Discov Med; 2011 Sep; 12(64):213-28. PubMed ID: 21955849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ventricular tachycardia on chronic fingolimod treatment for multiple sclerosis.
    Castillo-Trivino T; Lopetegui I; Alarcón-Duque JA; López de Munain A; Olascoaga J
    J Neurol Neurosurg Psychiatry; 2015 Aug; 86(8):931-2. PubMed ID: 25835036
    [No Abstract]   [Full Text] [Related]  

  • 12. New drugs may improve, complicate treatment for multiple sclerosis.
    Link H; Martin R
    Nat Med; 2010 Mar; 16(3):272. PubMed ID: 20208513
    [No Abstract]   [Full Text] [Related]  

  • 13. [Pharmacological properties and clinical efficacy of fingolimod hydrochloride (Imusera®/Gilenya®) for the treatment of multiple sclerosis].
    Chiba K; Yoshii N
    Nihon Yakurigaku Zasshi; 2012 Jun; 139(6):265-74. PubMed ID: 22728990
    [No Abstract]   [Full Text] [Related]  

  • 14. [A plan for risk management in the treatment of multiple sclerosis with gilenia (fingolimod)].
    Popova NF
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):110-3. PubMed ID: 21916166
    [No Abstract]   [Full Text] [Related]  

  • 15. FTY720 and central memory: out of sight, out of mind.
    Slavin AJ; Zamvil SS
    Neurology; 2010 Aug; 75(5):388-9. PubMed ID: 20610831
    [No Abstract]   [Full Text] [Related]  

  • 16. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
    Cohen JA; Chun J
    Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
    Massberg S; von Andrian UH
    N Engl J Med; 2006 Sep; 355(11):1088-91. PubMed ID: 16971715
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach.
    Gasperini C; Ruggieri S
    Drug Des Devel Ther; 2012; 6():175-86. PubMed ID: 22888218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis].
    Klatt J; Hartung HP; Hohlfeld R
    Nervenarzt; 2007 Oct; 78(10):1200-8. PubMed ID: 17668161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.
    Baumruker T; Billich A; Brinkmann V
    Expert Opin Investig Drugs; 2007 Mar; 16(3):283-9. PubMed ID: 17302523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.